



OPEN Hepatitis virus-associated B cell non-Hodgkin's lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription

Amanda N. Henning¹✉, Myagmarjav Budeebazar^{2,3}, Delgerbat Boldbaatar³, Dahgwahdorj Yagaanbuyant³, Davaadorj Duger², Khishigjargal Batsukh⁴, Samantha Muccilli¹, Jordan Pardoe¹, Lara Perinet¹, Olivia Conway¹, Darryl Owusu-Ansah¹, Kobe Robichaux¹, Ryan Baumann¹, Harvey J. Alter¹, Naranjargal Dashdorj^{3,5} & Valeria De Giorgi¹✉

Infection with HBV and its satellite virus HDV remain a significant global health issue due to their involvement in hepatic and extrahepatic diseases, including B cell non-Hodgkin's lymphoma (BNHL). Clinical and epidemiological evidence support a causal role for HBV in BNHL development, although mechanistic insight is lacking and the role of HDV infection in this process is unknown. To help elucidate viral drivers of B cell transformation, we performed RNA-sequencing on peripheral B cells from patients with HBV mono-infection, HBV/HDV co-infection, HBV/HDV-associated BNHL, BNHL without viral infection, and healthy donors. In this way, we sought to identify unique and shared transcriptional profiles associated with viral infection and transformation. Our data suggest dysregulated epigenetic and miRNA-mediated regulatory gene expression may be a potential common pathway for lymphomagenesis among viral- and non-viral-associated lymphoma. We also observed wide-spread upregulation of snoRNAs in B cells from virally infected patients, supporting a role for these non-coding RNAs in viral infection and, potentially, viral-associated lymphomagenesis. These results have identified novel areas for future functional studies on the effect of HBV and HDV infection on B cell activity and present additional therapeutic strategies that may benefit both viral- and non-viral associated BNHL.

Keywords B cell non-Hodgkin's lymphoma (BNHL), Epigenetic regulation, ncRNA (non-coding RNA), HBV (Hepatitis B Virus), HDV (Hepatitis D Virus), snoRNA (small nucleolar RNA)

Globally, an estimated 254 million people are living with chronic hepatitis B virus (HBV) infection, with an estimated 4.5% co-infected with the satellite virus, hepatitis delta (HDV)¹. HBV vaccination rates as well as HBV and HDV testing and treatment access vary by region. As a result, an estimated 87% of HBV infections go undiagnosed, and 1.2 million new HBV infections occur yearly¹. HBV and HBV/HDV co-infection remain a significant global health issue, as chronic infection of both are well-known contributors to hepatic diseases^{2,3}. Clinical and epidemiological studies also support a role for chronic HBV in the development of B cell non-Hodgkin's lymphoma (BNHL)³. Chronic infection significantly increases the risk of BNHL development, especially diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Further, HBV+ lymphoma

¹Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.

²Department of Gastroenterology, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.

³Liver Center, Ulaanbaatar, Mongolia. ⁴Center of Hematology and Bone Marrow Transplantation, First Central Hospital of Mongolia, Ulaanbaatar, Mongolia. ⁵Onom Foundation, Ulaanbaatar, Mongolia. ✉email: amanda.henning@nih.gov; valeria.degiorgi@nih.gov

patients have worse clinical outcomes than their HBV negative counterparts^{3–5}. The biological mechanisms responsible for this association are unknown. Although well-established as a hepatotropic virus, there is mounting evidence supporting HBV's lymphotropic ability. *In vivo* and *in vitro* studies have identified HBV DNA, mRNA, viral proteins, and viral integration events in bone marrow stem cells, PBMC, and mature B and T lymphocytes^{3,6,7}, and HBV DNA, viral proteins, and integration events have been detected in lymphoma tissue samples from HBV-associated NHL patients^{8,9}. These results suggest HBV may contribute to lymphoma development directly, through alterations stemming from B cell infection, in addition to possible indirect mechanisms. The role, if any, of HDV infection in BNHL development and its lymphotropic potential is unknown. However, HDV is dependent on HBsAg encapsulation for viral entry and exit², suggesting a shared tropism between the two viruses.

Given the prevalence of HBV and HDV infection throughout the world, a deeper understanding of the specific mechanisms and cellular changes responsible for driving HBV-associated BNHL, with or without HDV co-infection, are needed. To begin to address these outstanding questions, we investigated the transcriptome of peripheral B cells from chronic HBV and HBV/HDV co-infected patients collected from Mongolia, an area of endemic HBV and HDV infection^{10,11}. Our cohort consisted of patients with HBV mono-infection, HBV/HDV co-infection, HBV/HDV co-infection with BNHL, BNHL without viral infection, and healthy donors. In this way, we sought to capture early transcriptional alterations present in the periphery that may contribute to B cell transformation and lymphoma development. We report dysregulation of epigenetic and miRNA-mediated regulatory genes as a potential shared mechanism of B cell transformation for viral-associated and non-viral-associated BNHL, and upregulation of snoRNAs as a possible viral-specific mechanism. These results highlight novel areas of research that may benefit both the diagnosis and treatment of viral- and non-viral-associated BNHL and provide additional insight on the impact of HBV mono-infection and HBV/HDV co-infection on B cell activity.

Results

Clinical features of patient cohort

Patients were recruited for this study from the First Central Hospital of Mongolia and included individuals diagnosed with chronic HBV infection (HBV, $n = 4$), HBV co-infected with HDV (HBV/HDV, $n = 7$), co-infection of HBV and HDV with concomitant B cell non-Hodgkin's lymphoma (BNHL/HBV/HDV, $n = 3$), BNHL without viral infection (BNHL, $n = 6$), and healthy donors (HD, $n = 6$). The mean age of our cohort was 47 (range 28 – 70) and 42% of participants were female (Table 1). Viral infection-only groups were younger, on average, and the HBV/HDV group had a higher proportion of male patients. This is consistent with age- and sex-specific HBV and HDV prevalence differences in the Mongolian population^{10,11}. Co-infection with HDV is known to decrease HBV DNA levels², and, indeed, we observed this in our cohort. Conversely, we observed no difference in HDV RNA levels among co-infected groups (Table 1, Fig. S1A,B). HBV and HDV infection are known to contribute to liver disease in chronically infected patients^{2,3}. To evaluate liver functionality in our cohort, FIB-4 scores were calculated, which serve as a predictor of liver fibrosis¹². We observed no difference in FIB-4 scores across disease groups, and none of our patients exhibited an elevated score (Fig. S1C), indicating a low likelihood of advanced fibrosis in our cohort. All patients with HBV/HDV-associated BNHL (BNHL/HBV/HDV) were classified as diffuse large B cell lymphoma (DLBCL), and the majority presented with Stage III/IV disease (67%, $n = 2/3$; Table 1, Fig. S1D). Our BNHL-only group was more heterogeneous in subtype classification and included DLBCL (33%, $n = 2$), mucosa-associated lymphoid tissue (MALT) lymphoma (33%, $n = 2$), follicular lymphoma (FL, $n = 1$), and one case of undetermined subtype. The majority of BNHL-only patients (67%, $n = 4/6$) also presented with Stage III/IV disease (Table 1, Fig. S1D). Rates of HBV/HDV co-infection are very high in Mongolia¹¹, and during the collection period we were only able to obtain one HBV-associated BNHL sample without HDV co-infection. Due to the limited sample size for this group, this sample was not included in our analyses.

Transcriptional signature of immune suppression in HBV and HBV/HDV co-infected patients

We hypothesized that investigating transcriptional changes in peripheral B cells may help elucidate the mechanisms by which HBV and HDV infection contribute to B cell transformation and BNHL development. To this end, RNA-sequencing was performed on peripheral B cells isolated from our patient cohort (HBV, $n = 4$; HBV/HDV, $n = 7$; BNHL/HBV/HDV, $n = 3$; BNHL, $n = 6$; HD, $n = 6$), and we performed transcriptional analysis to identify differentially expressed genes (DEGs; \log_2 fold change > 1 or < -1 and adjusted p -value < 0.05) among pairwise comparisons. We identified the highest number of DEGs when comparing disease groups to HDs (432–626 DEGs), with the majority upregulated relative to HDs, and we observed far fewer DEGs in comparisons between disease groups (27–135 DEGs; Fig. 1A, Table S1). Gene set enrichment analysis (GSEA) indicated a consistent negative enrichment of gene sets associated with immune activation and cytokine signaling in peripheral B cells from chronic infection-only patients relative to BNHL patients and HDs. Negative enrichment of these gene sets was much less pronounced in BNHL/HBV/HDV samples (Figs. 1B,C, S1E, Table S2). Additionally, Ingenuity Pathway Analysis (IPA) was performed to identify predicted upstream regulators of DEGs (Table S3). In HBV mono-infected samples, inhibited upstream regulators (i.e. negative Z score) included pro-inflammatory cytokines, such as TNF, IL-6, IL-1, and IFN γ , as well as known B cell activators, including multiple stimulatory molecules and toll-like receptors. Conversely, upstream regulators predicted to be activated (i.e. positive Z score) in HBV mono-infected samples included kinase inhibitors targeting important signaling pathways downstream of BCR activation, including MAPK (U0126, SB203580, and PD98059) and PI3K (LY294002)^{13,14} (Fig. 1D). Our analyses, therefore, indicate peripheral B cells from chronically infected patients exhibited a transcriptional signature of generalized immune suppression, appearing less activated and less responsive to cytokine stimulation. This trend was strongest in HBV mono-infected samples and weakest in BNHL/HBV/HDV samples. Immunosuppressive phenotypes have been observed in other immune cell types in

	Total (n=26)	HD (n=6)	BNHL (n=6)	BNHL/HBV/HDV (n=3)	HBV/HDV (n=7)	HBV (n=4)
Age						
Mean (SD)	47.3 (12.9)	47.7 (12.4)	54.0 (9.6)	67.3 (2.3)	38.7 (6.7)	36.5 (7.9)
Range	28–70	28–64	37–65	66–70	31–46	30–48
Female Sex, n (%)						
n (%)	11 (42)	2 (33)	4 (67)	2 (67)	1 (14)	2 (50)
HBV DNA detected						
n (%)	n/a	n/a	n/a	1 (33.3)	6 (85.7)	4 (100)
HBV DNA (log ₁₀ IU/mL)						
Mean (SD)	n/a	n/a	n/a	2.48 (n/a)	2.60 (1.28)	6.23 (1.19)
Range	n/a	n/a	n/a	–	1.00–4.10	4.87–7.74
HDV RNA detected						
n (%)	n/a	n/a	n/a	2 (66.7)	7 (100)	n/a
HDV RNA (log ₁₀ IU/mL)						
Mean (SD)	n/a	n/a	n/a	4.67 (0.56)	4.99 (2.10)	n/a
Range	n/a	n/a	n/a	4.27–5.06	1.11–7.26	n/a
BNHL Subtype ^a , n (%)						
DLBCL	n/a	n/a	2 (33.3)	3 (100)	n/a	n/a
FL	n/a	n/a	1 (16.7)	–	n/a	n/a
MALT lymphoma	n/a	n/a	2 (33.3)	–	n/a	n/a
Subtype not determined	n/a	n/a	1 (16.7)	–	n/a	n/a
Clinical stage ^b , n (%)						
Stage I	n/a	n/a	1 (16.7)	–	n/a	n/a
Stage II	n/a	n/a	1 (16.7)	1 (33.3)	n/a	n/a
Stage III	n/a	n/a	3 (50)	2 (66.7)	n/a	n/a
Stage IV	n/a	n/a	1 (16.7)	–	n/a	n/a

Table 1. Patient demographics and clinical characteristics. ^aAs outlined in Revised European-American Lymphoma classification and WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (Revised 4th ed). ^bAnn Arbor staging system. *DLBCL* diffuse large B cell lymphoma, *FL* follicular lymphoma, *MALT* mucosa-associated lymphoid tissue.

chronic HBV infection¹⁵, and our data suggest peripheral B cells may be similarly impaired, although functional studies are needed to test this hypothesis.

Investigation of anergic phenotypes in HBV/HDV-associated BNHL

In our prior study of HCV-associated BNHL¹⁶, we observed evidence of an anergic-like phenotype in peripheral B cells that included anergic gene expression patterns and clonal expansion. We sought to investigate whether these observations were recapitulated in HBV/HDV-associated BNHL. B cell anergy-associated gene sets^{17,18} were not significantly enriched in our BNHL/HBV/HDV samples (Fig. S1F). B cell clonal expansion was investigated using our RNA-seq data via the MiXCR analysis tool^{19,20}. We observed consistency in percent and number of aligned reads, clonotype count, and predicted immunoglobulin gene usage among sample groups (Fig. S1G–J). We identified only one BNHL/HDV patient with evidence of peripheral B cell clonal expansion, with a top-ranked clonotype frequency of 40.6% (Fig. 1E). The enriched clonotype had a unique CDR3 amino acid sequence of CQYYSTPGTF and predicted gene usage of *IGKV4-1* and *IGKJ2*. While expansion of this variable gene has been observed in HBV-associated DLBCL²¹, we did not observe wide-spread peripheral B cell expansion in our HBV/HDV-associated BNHL cohort or transcriptional evidence of B cell anergy. This is in contrast to our findings from HCV-associated BNHL patients, where peripheral clonal expansion was observed in all patients, supporting an indirect mechanism of action¹⁶. Our current results indicate clonal expansion may be a feature of HBV/HDV-associated BNHL, but it does not appear to be ubiquitous, and its relevance to HBV/HDV-mediated lymphomagenesis remains unclear.

Shared transcriptional dysregulation in chronically infected and BNHL patients

Most DEGs were found to be upregulated in peripheral B cells from disease groups when compared to HDs (Fig. 1A), and we sought to further investigate these upregulated genes to uncover transcriptional commonalities across disease states. We observed 185 genes to be significantly upregulated in HBV, HBV/HDV, BNHL/HDV/HDV, and BNHL samples relative to HDs (Fig. 2A). Gene ontology (GO) analysis of these genes revealed enrichment of GO terms related to epigenetic and transcriptional regulation, cytoskeleton structure, and RNA-mediated regulation (Fig. 2B, Table S4). Specifically, enriched epigenetic GO terms included broad terms related to chromatin organization and histone methylation, as well as regulatory complex-specific terms (Fig. 2C). Indeed, upregulated genes included several known components of the SWI/SNF and NuRD chromatin remodeling complexes, including *ARID1A/B* and *GATAD2A*, respectively, as well as members of the COMPASS histone




Fig. 1. Transcriptional Analysis of Peripheral B Cells. (A) Stacked bar graph demonstrating the number of upregulated (white) and downregulated (gray) DEGs by comparison group. (B) Significantly enriched gene sets (y-axis) related to cytokine signaling and immune activation. Enrichment (NES) indicated by color and circle size denotes p-value. (C) Individual GSEA plots for Hallmark Inflammatory Response (top) and TNF α Signaling (bottom) gene sets in HBV vs HD. (D) Significantly enriched predicted upstream regulators from IPA. Enrichment Z score and p-value indicated by color and circle size, respectively. Predicted regulators are grouped based on function. (E) Frequency of the top-ranked clone, as defined by CDR3 nucleotide (CDR3nt) sequence. CDR3nt and amino acid (CDR3aa) sequence given for the indicated top-ranked clone. Graph displays mean \pm SEM, with individual patient values indicated by circles. DEG, differentially expressed gene; FDR, false discovery rate; HD, healthy donor; NES, normalized enrichment score.

methyltransferase complex, including *KMT2A/B/D* and *SETD1A/B*. Additionally, several well-known histone acetyltransferases (*BRD4*, *CREBBP*, *EP300*) and histone deacetylases (*BCOR*, *NCOR1/2*) were upregulated (Fig. 2C). GO terms related to RNA-mediated regulation were highly enriched, and annotated genes included critical components facilitating miRNA-mediated gene silencing, including members of the RISC complex (*TNRC6A*, *TNRC6B*, and *TNRC6C*)²², *CNOT3*, a component of the mRNA deadenylase CCR4-NOT complex²², and the translation initiation factor *EIF4G1*²³ (Fig. 2C). Peripheral B cells from chronically infected patients, therefore, shared a transcriptional phenotype of dysregulated epigenetic and miRNA-mediated regulatory gene expression with B cells from BNHL patients, suggesting these regulatory pathways may be involved in both viral- and non-viral-associated lymphomagenesis.

Elevated snoRNA expression as a possible viral-specific mechanism of lymphomagenesis

In addition to identifying shared pathways among disease groups, we were interested in dysregulated pathways that may be unique to chronic hepatitis infection. We observed an enrichment of small nucleolar RNAs





Fig. 2. Shared Transcriptional Dysregulation in Chronically Infected and BNHL Patients. **(A)** Area proportional Venn diagram illustrating the overlap of upregulated DEGs between indicated comparison groups. **(B)** Summary of manual annotation of significant GO terms ($n = 223$) identified by GO analysis of $n = 185$ commonly upregulated genes across disease groups vs HDs. **(C)** Most significantly enriched GO terms from the Epigenetic Regulation and RNA-mediated Regulation groups referenced in B are listed (y-axis). GO term enrichment shown on the x-axis, p-value indicated by color, and the number of DEGs annotated to each GO term indicated by circle size. Differentially expressed genes of interest are listed and grouped by function/complex.

(snoRNAs) among upregulated genes in chronically infected groups relative to healthy donors (Fig. 3A). Across all comparison groups, we observed 69 unique snoRNAs to be differentially expressed (DE), the majority of which were upregulated in B cell samples from HBV mono-infection patients relative to HDs ($n = 65$) (Fig. 3B, Table S1). snoRNAs are a type of small non-coding RNA, whose canonical function is to aid in ribosome biogenesis within the nucleolus by directing post-transcriptional nucleotide modifications of ribosomal RNA



(rRNA)²⁴. Importantly, viruses, including HBV and HDV, are known to hijack aspects of nucleolar activity, including ribosomal biogenesis, to promote viral replication and translation^{25,26}. Traditionally, snoRNAs are encoded in intronic regions of protein-coding and non-coding host genes, and the gene products of protein coding snoRNA host genes tend to be involved in ribosomal biogenesis, regulation of translation, or RNA processing²⁷. We observed this to be the case for our DE snoRNAs. Almost all DE snoRNAs (n = 68/69) were intronically located, and host genes consisted of long-noncoding RNAs (lncRNAs; 30%), ribosomal subunits (28%), ribosome biogenesis factors (RBF, 7%), or encoded proteins involved in RNA binding/regulation (9%) (Fig. 3C). Despite their intragenic location, snoRNA expression does not always correlate with host gene expression^{27,28}. Fafard-Couture et al.²⁸ observed that snoRNAs whose expression was positively correlated to their host genes tended to reside within ribosomal protein genes. Indeed, in our cohort, correlation values (Pearson correlation coefficient, r) for snoRNA-host gene pairs were elevated for host genes encoding ribosomal subunits compared to host genes with other functions (Fig. 3D). Additionally, despite differential expression of their intronic snoRNA, only three host genes were found to be differentially expressed, corresponding to five DE

◀ **Fig. 3.** Elevated snoRNA Expression as a Possible Viral-specific Mechanism of Lymphomagenesis. (A) Area proportional Venn diagram highlighting the number of differentially expressed (DE) snoRNAs among chronically infected groups. (B) Volcano plot of upregulated DE snoRNAs. Comparison groups with the highest number of DE snoRNAs are shown. Number of snoRNAs per group indicated in legend. Fold change and p-value cutoffs for differential expression indicated on x-axis and y-axis, respectively (dashed and dotted lines). Specific snoRNAs of interest are labeled and indicated with colored shapes. (C) Manual classification of DE snoRNA host gene function. (D) Violin plot of gene expression correlation (Pearson r) between DE snoRNAs and their corresponding host gene. Host genes are grouped by their function. Red circles indicate snoRNA-host gene pairs where the host gene is also differentially expressed. Plots show median (dashed line) and 25th and 75th percentiles (dotted lines). (E) Significantly enriched GO terms from transcriptome-wide analysis of genes whose expression highly correlates (Pearson $r > 0.7$) with at least one DE snoRNA. GO terms listed on the y-axis and color coded based on related function. Bars indicate enrichment ratio (top x-axis), and circles indicate p-value (bottom x-axis). (F) DE status of genes correlated with at least one of the DE snoRNAs identified in our study. DE, differentially expressed; FDR, false discovery rate; HD, healthy donor; lncRNA, long non-coding RNA; RBF, ribosome biogenesis factor. $p < 0.0001$, ****.

snoRNA-host gene pairs (Fig. 3D). Together, this indicates that our observed snoRNA differential expression is not solely driven by host gene expression differences. We expanded our correlation analysis to include all expressed genes and observed 463 genes with high positive correlation with at least one DE snoRNA (Pearson $r > 0.7$). GO analysis of this correlated gene set indicated enrichment of Mediator complex and ribonucleoprotein genes as well as ribosomal subunits (Fig. 3E). Although the majority of correlated genes were not differentially expressed (Fig. 3F), correlation analysis suggests possible transcriptional co-regulation of DE snoRNAs with numerous genes involved in ribosome biogenesis. In this way, upregulation of snoRNA genes in peripheral B cells from chronically infected patients may indicate infection-dependent alterations in ribosomal biogenesis or composition.

snoRNAs have gained increasing interest for their role in cancer detection and progression, with numerous reports of specific snoRNAs serving as diagnostic and/or prognostic biomarkers and as having oncogenic and tumor suppressive roles²⁴. Often, effects on cancer development are driven by non-canonical snoRNA functions that can include direct regulation of mRNA expression at the post-transcriptional or translational level^{24,29}. Of our DE snoRNAs, we found 31 that had documented roles in cancer or mRNA regulation (Table 2). This included three snoRNAs that were upregulated in all chronically infected groups relative to HDs (*SNORD33*, *SNORD46*, and *SNORD76*; Fig. 3B). Cancer-associated roles were reported across several histologies, and many snoRNAs appeared to have cancer type-specific effects. For instance, functional studies support an oncogenic role for *SNORD76* in hepatocellular carcinoma (HCC) and a tumor suppressive role in glioblastoma, where it acts to either promote or inhibit cell proliferation, respectively^{30,31}. Overall, our transcriptional analysis indicated elevated snoRNA expression may be a viral-specific phenomenon in peripheral B cells, and it presents the intriguing hypothesis that snoRNA-mediated alterations to ribosomal biogenesis or mRNA transcription and translation may be a mechanism driving viral-associated lymphomagenesis.

Discussion

Infection with HBV and its satellite virus HDV remain a significant global health issue, with chronic infection contributing to increased risks of hepatic and extrahepatic diseases, including B cell non-Hodgkin's lymphoma (BNHL)³. Clinical and epidemiological evidence support a role for chronic HBV in BNHL development³. However, the precise mechanisms by which HBV may contribute to lymphomagenesis and the contributions of chronic HDV infection are unclear. To begin to address these gaps in knowledge, we sought to investigate the peripheral B cell transcriptome of HBV/HDV-associated BNHL in relation to non-viral associated BNHL as well as chronic infection alone and healthy donors. By analyzing circulating B cells from chronically infected patients both with and without lymphoma, we hoped to identify early transcriptional changes that may contribute to lymphomagenesis via either direct or indirect mechanisms.

Differential expression analysis revealed that all disease states exhibited upregulation of epigenetic regulatory genes and genes required for miRNA-mediated gene silencing. Tightly controlled epigenetic regulation is an essential component of normal B cell development³², and disruption of these regulatory pathways is frequently observed in lymphomas³³. Indeed, epigenetic regulators are frequently mutated in BNHL³³, including many of our DEGs, such as *KMT2D*, *CREBBP*, *EP300*, and *ARID1A*, which are each individually found to be mutated in approximately 5 – 25% of non-viral and HBV-associated DLBCL cases^{5,34–36}. Epigenetic regulatory proteins are also known to be affected by viral infection, including chronic HBV. In hepatocytes, the HBV viral genome translocates to the nucleus where it utilizes host histones and epigenetic modifying proteins to establish covalently closed circular DNA (cccDNA), which is required for efficient viral transcription and replication. The viral protein HBx is known to aid in this process and has been shown to directly interact with host epigenetic proteins, including p300/*EP300* and CBP/*CREBBP*^{37,38}. In this way, the upregulation of epigenetic modifiers we observed in peripheral B cells may aid in HBV replication in a lymphotropic model of infection, although functional studies would be needed to test this hypothesis. miRNA-mediated regulation of gene expression represents another regulatory mechanism employed during normal B cell development and activation whose dysregulation contributes to B cell transformation³². We observed upregulation of multiple genes encoding proteins required for miRNA-mediated mRNA regulation. In particular, *TNRC6A*, *TNRC6B*, and *TNRC6C* form a critical component of the RISC complex, which facilitates miRNA-mediated mRNA decay and translational repression. This regulatory activity occurs within membraneless, cytoplasmic domains called processing bodies

snoRNA function	Differentially expressed snoRNA(s)
Cancer biomarker (diagnostic and/or prognostic)	
AML	SNORA31 ⁵⁶
BC	SNORA10 ⁵⁷ , SNORA24 ⁵⁷ , SNORA52 ⁵⁷ , SNORA66 ⁵⁸ , SNORD33 ⁵⁹ , SNORD46 ⁶⁰ , SNORD89 ⁶⁰
CRC	SNORD16 ⁶¹ , SNORD57 ⁶² , SNORD67 ⁶³
DLBCL	SNORA60 ⁶⁴ , SNORA66 ⁶⁴
HCC	SNORA52 ⁶⁵ , SNORD46 ⁶⁶ , SNORD76 ³⁰
MM	SNORD27 ⁶⁷
NSCLC	SNORD104 ⁶⁸ , SNORD28 ⁶⁹ , SNORD33 ⁷⁰ , SNORD55 ⁷¹ , SNORD60 ⁷² , SNORD66 ⁷⁰ , SNORD76 ⁷⁰ , SNORD83A ⁷³
OC	SNORD89 ⁷⁴
PC	SNORA14B ⁷⁵
PCa	SNORA10 ⁷⁶
RCC	SNORD35B ⁷⁷ , SNORD60 ⁷⁷
SKCM/UM	SNORA31 ⁷⁸ , SNORD12 ⁷⁹ , SNORD83A ⁷⁸
Oncogenic activity	
BC	SNORD28 ⁴⁸ , SNORD46 ⁸⁰ , SNORD50A ⁴⁷
CRC	SNORA24 ⁴⁶ , SNORD16 ⁶¹
EC	SNORD104 ⁵⁰ , SNORD60 ⁵¹ , SNORD89 ⁴⁹
HCC	SNORD76 ³⁰
NSCLC	SNORA7A ⁸¹ , SNORD46 ⁸⁰
OC	SNORA81 ⁸² , SNORD89 ⁷⁴
OS	SNORA7A ⁸³
PC	SNORD35A ⁸⁴
Tumor suppressive activity	
GBM	SNORD47 ⁸⁵ , SNORD76 ³¹
HCC	SNORA24 ⁸⁶
KRAS-driven cancers	SNORD50A ⁸⁷
Regulation of mRNA splicing and processing	SCARNA1 ⁸⁸ , SNORD27 ⁸⁹ , SNORD50A ⁹⁰ , SNORD83B ⁹¹
Effect on ribosome heterogeneity	SNORA33 ⁹²

Table 2. Role of differentially expressed snoRNAs in cancer and post-transcriptional regulation. *AML* acute myeloid leukemia, *BC* breast cancer, *CRC* colorectal cancer, *DLBCL* diffuse large B cell lymphoma, *EC* endometrial cancer, *GBM* glioblastoma, *HCC* hepatocellular carcinoma, *MM* multiple myeloma, *NSCLC* non-small cell lung cancer, *OC* ovarian cancer, *OS* osteosarcoma, *PC* pancreatic cancer, *PCa* prostate cancer, *RCC* renal cell carcinoma, *SKCM* human skin cutaneous melanoma, *UV* uveal melanoma.

(P bodies)²². Alterations to P body activity and composition have been implicated in the development of multiple carcinoma subtypes and represents a novel diagnostic marker and therapeutic target³⁹. Additionally, P body stability, number, and localization have been shown to be altered following viral infection^{40,41}, although it is unknown whether HBV or HDV infection affect their activity. Our results support additional studies on the specific role of P bodies in B cell biology, transformation, and chronic hepatitis infection. Altogether, the upregulation of epigenetic modifiers and RNA-dependent regulatory genes we observed in viral- and non-viral-associated BNHL and chronic infection would not only increase the opportunity for loss- or gain-of-function mutations at these loci⁴², but could alter the transcriptomic, epigenomic, and/or translational landscape of circulating B cells (Fig. 4). In this way, these gene expression changes may be a shared molecular response contributing to a pro-lymphomagenic cellular environment and represent a potential common pathway driving viral and non-viral lymphomagenesis.

Despite compelling clinical evidence supporting the role of HBV in BNHL development, there is very little information on the mechanisms behind this association or the functional effects of chronic infection on B cell activity. Furthermore, there is virtually no information on the impact of HBV/HDV co-infection. Our transcriptional profiling has identified multiple biological programs that appear dysregulated in peripheral B cells during chronic infection with HBV and HBV/HDV that may be contributing to viral-associated BNHL development (Fig. 4). In particular, we observed upregulation of numerous snoRNAs in B cells from chronically infected patients, especially HBV mono-infected patients. Canonical snoRNA activity occurs within the nucleolus, where they interact with ribosome biogenesis factors (RBFs) to add 2'-O-methylation or pseudouridylation modifications to rRNAs, facilitating ribosome biogenesis²⁴. We observed differentially expressed snoRNAs to be positively correlated with RBF and ribosomal protein gene expression. This suggests possible co-regulation of these genes and supports the hypothesis that chronic HBV/HDV co-infection and HBV mono-infection may result in wide-spread alterations to ribosome biogenesis in peripheral B cells. HBV and HDV are known to commandeer nucleolar activity, including ribosome biogenesis, to support viral replication and translation^{25,26}. In a lymphotropic model of infection, this has the potential to promote B cell transformation. Indeed, in HBV-




Fig. 4. Proposed Direct Mechanisms of HBV and HBV/HDV-associated B cell Transformation. Based on our transcriptional analyses, we illustrate possible direct mechanisms by which HBV and HDV may be contributing to B cell transformation in a lymphotropic model of infection. Black text indicates dysregulated pathways that may be shared between viral- and non-viral-associated BNHL, and red text indicates dysregulated pathways and interactions that may be unique to HBV and HDV infection. Dashed line indicates hypothesized interaction warranting further investigation. Figure created using BioRender (Henning, A. (2025) <https://BioRender.com/5k2rgb3>). cccDNA, covalently closed circular DNA; HBx, HBV-encoded oncogene X protein; HDAg, hepatitis delta antigen; miRNA, micro RNA; mRNA, messenger RNA; P body, processing body; RBF, ribosome biogenesis factor; RISC, RNA-induced silencing complex; RP, ribosomal protein; rRNA, ribosomal RNA; snoRNA, small nucleolar RNA.

associated HCC, HBx was found to interact with the RBF nucleophosmin in the nucleolus to promote ribosome biogenesis, resulting in increased cell proliferation and transformation⁴³. Furthermore, replication of HDV genomic RNA occurs in the nucleolus, where HDAg interacts with RBFs to initiate antigenomic RNA synthesis needed for viral propagation^{44,45}. snoRNAs have also been shown to have direct roles in cancer development²⁴, and many of our differentially expressed snoRNAs have demonstrated oncogenic activity (Table 2). *SNORA24*, *SNORD28*, and *SNORD50A* have been shown to negatively regulate p53 protein stability in colorectal cancer and breast cancer^{46–48}. *SNORD28* promotes oncogenesis via miRNA-like activity directed against the p53-stabilizing protein TAF9B⁴⁸, while *SNORD50A* promotes the ubiquitination and subsequent cytoplasmic sequestration of

the p53-stabilizing protein GMPS⁴⁷. In endometrial cancer, *SNORD60*, *SNORD89*, and *SNORD104* promote tumorigenesis by directing their 2'-O-methylation activity towards protein-coding mRNAs. This post-transcriptional modification affects the stability or translation efficiency of target mRNAs, leading to alterations in downstream signaling^{49–51}. While our current study cannot determine if snoRNA expression changes are due to indirect or direct effects of chronic infection, the known nucleolar activity of HBV and HDV together with their reported lymphotropic potential support the intriguing hypothesis that snoRNA upregulation may be a direct mechanism contributing to viral-mediated B cell transformation and represents a novel area of future investigation.

In the current study, we have identified a number of specific biological pathways that may be contributing to HBV and HBV/HDV-associated BNHL development. Our identification of P bodies as possible effectors of downstream alterations in both viral- and non-viral associated BNHL represents a novel finding with therapeutic implications and warrants additional investigation. Additionally, viral-specific snoRNA upregulation represents a possible novel mechanism contributing to B cell transformation at the chronic infection stage, and it is consistent with known relationships between HBV and HDV infection and nucleolar activity. We cannot, however, determine whether viral-specific alterations are the result of indirect mechanisms that are occurring as a cellular response to viral infection or are initiated via direct mechanisms following viral infection of B cells. In HBV-associated lymphomas, evidence of viral integration events, viral-specific mutational signatures, and inconsistent reports of biased immunoglobulin gene usage support direct mechanisms as the primary driver of HBV-mediated B cell transformation^{4,5,8}. However, while evidence supports the lymphotropic potential of HBV^{3,6,7}, it is still an ongoing area of research in the field. The RNA-sequencing method used in this study was not designed to detect viral transcripts in patient B cells, and our limited amount of patient material prevented viral-specific sequencing for all patients. However, we were able to perform unbiased RNA-sequencing on one HBV+ mono-infected patient and were able to detect HBV transcripts with high sequence identity (>90%) and complete genome coverage (Fig. S2). While this finding warrants additional investigation in a larger cohort, it further supports HBV's lymphotropic potential and the opportunity for B cell transformation via direct mechanisms. This does not, however, exclude the possibility that indirect mechanisms may also be employed. In particular, extracellular vesicles can facilitate HBV propagation and crosstalk between hepatocytes and lymphocytes, disseminating not only viral DNA and proteins, but host proteins and RNAs that can mediate functional changes in recipient cells to support disease progression⁵². Caveats to our study include a limited sample size and subtype heterogeneity in the BNHL-only cohort. Additionally, we were unable to obtain HBV-associated BNHL samples without HDV co-infection, and our viral-only group skewed younger. Despite these limitations, our results support novel hypotheses regarding the mechanisms underlying the epidemiological association between chronic hepatitis infection and BNHL development. Specifically, we identified epigenetic and miRNA-mediated regulation as possible effectors of downstream alterations in both viral- and non-viral associated BNHL and snoRNA upregulation as a possible novel viral-specific mechanism contributing to B cell transformation. These data begin to shed light on an understudied area in the field and support additional, functional studies that will have significant diagnostic and therapeutic implications for patients with both chronic infection and lymphoma.

Methods

Patient population and clinical testing

Patients were recruited for this study at the First Central Hospital of Mongolia (Ulaanbaatar, Mongolia) according to study protocol policies approved by the Ethics Committee of the Ministry of Health (No. 4, approval date 6/19/2017). Informed consent was obtained from all patients, and all methods were performed in accordance with relevant guidelines and regulations. BNHL diagnosis was determined using cytological or pathological examination and guidelines outlined in the Revised European-American Lymphoma classification⁵³ and the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (Revised 4th edition)⁵⁴. Clinical blood tests were performed at the First Central Hospital of Mongolia, and viral testing took place at the Liver Center (Ulaanbaatar, Mongolia). HBV DNA and HCV RNA testing was performed using the Xpert® HBV and HCV Viral Load assays, respectively, run on the automated, closed-system GeneXpert® IV or XVI platform (Cepheid; Sunnyvale, CA, USA). Anti-HCV antibody detection was conducted via the HCV Ab Plus Rapid Test (CTK Biotech; Poway, CA, USA). Samples testing positive were subject to HCV RNA quantitative testing. Qualitative testing of HBsAg was conducted using the HBsAg Rapid test (CTK Biotech; Poway, CA, USA). HDV RNA quantification was conducted using an in-house developed assay⁵⁵. The FIB-4 scoring metric was used to estimate liver fibrosis in patients using the formula $(Age \times AST) / (Platelets \times \sqrt{ALT})$. Patients with FIB-4 scores above 3.25 are likely to suffer from advanced fibrosis, while patients with scores below 1.45 are likely free from fibrosis¹².

PBMC sample processing, B cell isolation and RNA-sequencing

Whole blood collection and PBMC isolation was performed by collaborators in Mongolia at the Liver Center as outlined in Henning et al.¹⁶. B cell isolation, RNA isolation, and RNA-sequencing was performed as previously described¹⁶. Briefly, B cells were isolated from thawed PBMC samples via the EasySep Human B cell Isolation kit (StemCell Tech) and RNA was isolated using the RNeasy Plus Micro kit (Qiagen). The TruSeq RNA Exome kit (Illumina) was used for library preparation, and RNA-sequencing was performed on a NextSeq 550 instrument (Illumina) using High Output flow cells (v2.5, 150 cycles; Illumina).

Bioinformatic and statistical analysis

The BaseSpace Sequencing Hub (Illumina) was used to evaluate sequencing run quality metrics and for alignment. Reads were aligned using the RNA-Seq Alignment application (v2.0.2, hg19 reference genome),

which utilizes the STAR aligner and Salmon for transcript quantification. Sequencing files have been deposited in the GEO repository under GSE279755. BCR repertoire analysis using RNA-seq input data was conducted using the MiXCR Immune Repertoire Analyzer application (v2.1.11)^{19,20}. Differential expression analysis was performed in R (v4.0.2) using the DESeq2 package (v1.28.1; DESeqDataSet design = ~ Batch + Diagnosis), and differentially expressed genes (DEGs) were defined as those with a log₂ fold change < -1 or > 1 and a Benjamini–Hochberg adjusted P-value of < 0.05. Bioinformatic tools used for transcriptional investigations included: gene set enrichment analysis (GSEA, v4.0.3), Ingenuity Pathway Analysis (IPA, Qiagen), and gene ontology analysis (WebGestalt tool, www.webgestalt.org). Transcriptome-wide correlation (Pearson correlation coefficient, r) was performed in R, and figures were created using R and GraphPad Prism (v10.1.2). Statistical analysis was performed in GraphPad. An unpaired T test or nonparametric Mann–Whitney test was used for analyses consisting of 2 groups. For groups of more than 2, a one-way ANOVA or nonparametric Kruskal–Wallis test was performed, with Tukey’s or Dunn’s correction for multiple comparisons, respectively.

Data availability

The datasets generated and analyzed during the current study are available in the GEO repository, <https://www.ncbi.nlm.nih.gov/geo/>, under accession number GSE279755. Additional information and files are available on reasonable request.

Received: 24 June 2025; Accepted: 1 January 2026

Published online: 10 January 2026

References

1. Global hepatitis report 2024: action for access in low- and middle-income countries. (World Health Organization, Geneva, 2024).
2. Mentha, N., Clement, S., Negro, F. & Alfaïate, D. A review on hepatitis D: From virology to new therapies. *J. Adv. Res.* **17**, 3–15. <https://doi.org/10.1016/j.jare.2019.03.009> (2019).
3. Rosenberg, M. et al. Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities. *Front. Oncol.* **13**, 1275800. <https://doi.org/10.3389/fonc.2023.1275800> (2023).
4. Ren, W. et al. Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. *Blood Adv.* **6**, 2731–2744. <https://doi.org/10.1182/bloodadvances.2021006410> (2022).
5. Ren, W. et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. *Blood* **131**, 2670–2681. <https://doi.org/10.1182/blood-2017-11-817601> (2018).
6. Svicher, V. et al. New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis. *Front. Oncol.* **13**, 1143258. <https://doi.org/10.3389/fonc.2023.1143258> (2023).
7. Coffin, C. S., Mulrooney-Cousins, P. M. & Michalak, T. I. Hepadnaviral lymphotropism and its relevance to HBV persistence and pathogenesis. *Front. Microbiol.* **12**, 695384. <https://doi.org/10.3389/fmicb.2021.695384> (2021).
8. Li, M. et al. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. *Int. J. Cancer* **147**, 2199–2209. <https://doi.org/10.1002/ijc.33027> (2020).
9. Wang, Y. et al. Capable infection of hepatitis B virus in diffuse large B-cell lymphoma. *J. Cancer* **9**, 1575–1581. <https://doi.org/10.7150/jca.24384> (2018).
10. Dashtseren, B. et al. Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey amongst Mongolian adults. *J. Viral. Hepat.* **24**, 759–767. <https://doi.org/10.1111/jvh.12697> (2017).
11. Chen, X. et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. *Hepatology* **66**, 1739–1749. <https://doi.org/10.1002/hep.28957> (2017).
12. Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* **43**, 1317–1325. <https://doi.org/10.1002/hep.21178> (2006).
13. Wen, Y. et al. The regulators of BCR signaling during B cell activation. *Blood Sci.* **1**, 119–129. <https://doi.org/10.1097/BS9.000000000000026> (2019).
14. Khiem, D., Cyster, J. G., Schwarz, J. J. & Black, B. L. A p38 MAPK-MEF2C pathway regulates B-cell proliferation. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 17067–17072. <https://doi.org/10.1073/pnas.0804868105> (2008).
15. Li, T. Y., Yang, Y., Zhou, G. & Tu, Z. K. Immune suppression in chronic hepatitis B infection associated liver disease: A review. *World J. Gastroenterol.* **25**, 3527–3537. <https://doi.org/10.3748/wjg.v25.i27.3527> (2019).
16. Henning, A. N. et al. Peripheral B cells from patients with hepatitis C virus-associated lymphoma exhibit clonal expansion and anergic-like transcriptional profile. *iScience* **26**, 105801. <https://doi.org/10.1016/j.isci.2022.105801> (2023).
17. Charles, E. D. et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. *Blood* **117**, 5425–5437. <https://doi.org/10.1182/blood-2010-10-312942> (2011).
18. Isnardi, I. et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. *Blood* **115**, 5026–5036. <https://doi.org/10.1182/blood-2009-09-243071> (2010).
19. Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. *Nat. Methods* **12**, 380–381. <https://doi.org/10.1038/nmeth.3364> (2015).
20. Bolotin, D. A. et al. Antigen receptor repertoire profiling from RNA-seq data. *Nat. Biotechnol.* **35**, 908–911. <https://doi.org/10.1038/nbt.3979> (2017).
21. Deng, L. et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. *Oncotarget* **6**, 25061–25073. <https://doi.org/10.18632/oncotarget.4677> (2015).
22. Niaz, S. & Hussain, M. U. Role of GW182 protein in the cell. *Int. J. Biochem. Cell Biol.* **101**, 29–38. <https://doi.org/10.1016/j.biocel.2018.05.009> (2018).
23. Ryu, I., Park, J. H., An, S., Kwon, O. S. & Jang, S. K. eIF4GI facilitates the MicroRNA-mediated gene silencing. *PLoS ONE* **8**, e55725. <https://doi.org/10.1371/journal.pone.0055725> (2013).
24. Huang, Z. H., Du, Y. P., Wen, J. T., Lu, B. F. & Zhao, Y. snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology. *Cell Death Discov.* **8**, 259. <https://doi.org/10.1038/s41420-022-01056-8> (2022).
25. Dong, H. J., Zhang, R., Kuang, Y. & Wang, X. J. Selective regulation in ribosome biogenesis and protein production for efficient viral translation. *Arch. Microbiol.* **203**, 1021–1032. <https://doi.org/10.1007/s00203-020-02094-5> (2021).
26. Iarovaia, O. V., Ioudinkova, E. S., Velichko, A. K. & Razin, S. V. Manipulation of cellular processes via nucleolus Hijacking in the course of viral infection in mammals. *Cells* <https://doi.org/10.3390/cells10071597> (2021).
27. Fafard-Couture, E., Jacques, P. E. & Scott, M. S. Motif conservation, stability, and host gene expression are the main drivers of snoRNA expression across vertebrates. *Genome Res.* **33**, 525–540. <https://doi.org/10.1101/gr.277483.122> (2023).

28. Fafard-Couture, E., Bergeron, D., Couture, S., Abou-Elela, S. & Scott, M. S. Annotation of snoRNA abundance across human tissues reveals complex snoRNA-host gene relationships. *Genome Biol.* **22**, 172. <https://doi.org/10.1186/s13059-021-02391-2> (2021).
29. Dupuis-Sandoval, F., Poirier, M. & Scott, M. S. The emerging landscape of small nucleolar RNAs in cell biology. *Wiley Interdiscip. Rev. RNA* **6**, 381–397. <https://doi.org/10.1002/wrna.1284> (2015).
30. Wu, L. et al. Clinical significance of C/D box small nucleolar RNA U76 as an oncogene and a prognostic biomarker in hepatocellular carcinoma. *Clin. Res. Hepatol. Gastroenterol.* **42**, 82–91. <https://doi.org/10.1016/j.clinre.2017.04.018> (2018).
31. Chen, L. et al. SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. *Sci. Rep.* **5**, 8588. <https://doi.org/10.1038/srep08588> (2015).
32. Bao, Y. & Cao, X. Epigenetic control of B cell development and B-Cell-related immune disorders. *Clin. Rev. Allergy Immunol.* **50**, 301–311. <https://doi.org/10.1007/s12016-015-8494-7> (2016).
33. Jiang, Y., Dominguez, P. M. & Melnick, A. M. The many layers of epigenetic dysfunction in B-cell lymphomas. *Curr. Opin. Hematol.* **23**, 377–384. <https://doi.org/10.1097/MOH.0000000000000249> (2016).
34. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat. Genet.* **43**, 830–837. <https://doi.org/10.1038/ng.892> (2011).
35. Cao, B. et al. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics. *BMC Med. Genomics* **17**, 84. <https://doi.org/10.1186/s12920-024-01866-y> (2024).
36. Candelaria, M. et al. Characterizing the mutational landscape of diffuse large B-cell lymphoma in a prospective cohort of Mexican patients. *Int. J. Mol. Sci.* <https://doi.org/10.3390/ijms25179328> (2024).
37. Zeisel, M. B., Guerrieri, F. & Levrero, M. Host epigenetic alterations and hepatitis B virus-associated hepatocellular carcinoma. *J. Clin. Med.* <https://doi.org/10.3390/jcm10081715> (2021).
38. Koumbi, L. & Karayiannis, P. The epigenetic control of hepatitis B virus modulates the outcome of infection. *Front. Microbiol.* **6**, 1491. <https://doi.org/10.3389/fmicb.2015.01491> (2015).
39. Nsengimana, B. et al. Processing body (P-body) and its mediators in cancer. *Mol. Cell. Biochem.* **477**, 1217–1238. <https://doi.org/10.1007/s11010-022-04359-7> (2022).
40. Riggs, C. L., Kedersha, N., Ivanov, P. & Anderson, P. Mammalian stress granules and P bodies at a glance. *J. Cell. Sci.* <https://doi.org/10.1242/jcs.242487> (2020).
41. Perez-Vilaro, G. et al. Hepatitis C virus infection inhibits P-body granule formation in human livers. *J. Hepatol.* **62**, 785–790. <https://doi.org/10.1016/j.jhep.2014.11.018> (2015).
42. Park, C., Qian, W. & Zhang, J. Genomic evidence for elevated mutation rates in highly expressed genes. *EMBO Rep.* **13**, 1123–1129. <https://doi.org/10.1038/embor.2012.165> (2012).
43. Ahuja, R., Kapoor, N. R. & Kumar, V. The HBx oncoprotein of hepatitis B virus engages nucleophosmin to promote rDNA transcription and cellular proliferation. *Biochim. Biophys. Acta* **1783–1795**, 2015. <https://doi.org/10.1016/j.bbamcr.2015.04.012> (1853).
44. Huang, W. H., Yung, B. Y., Syu, W. J. & Lee, Y. H. The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication. *J. Biol. Chem.* **276**, 25166–25175. <https://doi.org/10.1074/jbc.M010087200> (2001).
45. Huang, W. H., Chen, Y. S. & Chen, P. J. Nucleolar targeting of hepatitis delta antigen abolishes its ability to initiate viral antigenomic RNA replication. *J. Virol.* **82**, 692–699. <https://doi.org/10.1128/JVI.01155-07> (2008).
46. Shen, L. et al. Involvement of the oncogenic small nucleolar RNA SNORA24 in regulation of p53 stability in colorectal cancer. *Cell Biol. Toxicol.* **39**, 1377–1394. <https://doi.org/10.1007/s10565-022-09765-7> (2023).
47. Su, X. et al. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPs interaction promotes the growth of p53 wild-type breast cancers by degrading p53. *Cell. Death Differ.* **28**, 2450–2464. <https://doi.org/10.1038/s41418-021-00762-7> (2021).
48. Yu, F. et al. p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNA. *PLoS ONE* **10**, e0129190. <https://doi.org/10.1371/journal.pone.0129190> (2015).
49. Bao, H. J. et al. Box C/D snoRNA SNORD89 influences the occurrence and development of endometrial cancer through 2'-O-methylation modification of Bim. *Cell Death Discov.* **8**, 309. <https://doi.org/10.1038/s41420-022-01102-5> (2022).
50. Lu, B. et al. C/D box small nucleolar RNA SNORD104 promotes endometrial cancer by regulating the 2'-O-methylation of PARP1. *J. Transl. Med.* **20**, 618. <https://doi.org/10.1186/s12967-022-03802-z> (2022).
51. Wu, W. et al. SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway. *Mol. Carcinog.* **62**, 413–426. <https://doi.org/10.1002/mc.23495> (2023).
52. Yuan, X., Huang, C. & Ran, Y. Exosome in HBV infection: current concepts and future perspectives. *Front. Cell. Infect. Microbiol.* **15**, 1547525. <https://doi.org/10.3389/fcimb.2025.1547525> (2025).
53. Harris, N. L. et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* **84**, 1361–1392 (1994).
54. Swerdlow SH, C. E., Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. (IARC, Lyon, 2017).
55. Karatayli, E. et al. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. *J. Clin. Virol.* **60**, 11–15. <https://doi.org/10.1016/j.jcv.2014.01.021> (2014).
56. Huang, R., Liao, X. & Li, Q. Integrative genomic analysis of a novel small nucleolar RNAs prognostic signature in patients with acute myelocytic leukemia. *Math. Biosci. Eng.* **19**, 2424–2452. <https://doi.org/10.3934/mbe.2022112> (2022).
57. Schulten, H. J. et al. Comprehensive molecular biomarker identification in breast cancer brain metastases. *J. Transl. Med.* **15**, 269. <https://doi.org/10.1186/s12967-017-1370-x> (2017).
58. Taghizadeh, E., Heydarheydari, S., Saberi, A., JafarpoorNesheli, S. & Rezaei, S. M. Breast cancer prediction with transcriptome profiling using feature selection and machine learning methods. *BMC Bioinform.* **23**, 410. <https://doi.org/10.1186/s12859-022-04965-8> (2022).
59. Wang, B. et al. A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. *Mol. Cancer* **21**, 22. <https://doi.org/10.1186/s12943-022-01504-0> (2022).
60. Krishnan, P. et al. Profiling of small nucleolar RNAs by next generation sequencing: potential new players for breast cancer prognosis. *PLoS ONE* **11**, e0162622. <https://doi.org/10.1371/journal.pone.0162622> (2016).
61. He, J. Y. et al. Small nucleolar RNA, C/D Box 16 (SNORD16) acts as a potential prognostic biomarker in colon cancer. *Dose Response* **18**, 1559325820917829. <https://doi.org/10.1177/1559325820917829> (2020).
62. Tosar, J. P., Garcia-Silva, M. R. & Cayota, A. Circulating SNORD57 rather than piR-54265 is a promising biomarker for colorectal cancer: common pitfalls in the study of somatic piRNAs in cancer. *RNA* **27**, 403–410. <https://doi.org/10.1261/rna.078444.120> (2021).
63. Huang, L. et al. Prognostic value of small nucleolar RNAs (snoRNAs) for colon adenocarcinoma based on RNA sequencing data. *Pathol. Res. Pract.* **216**, 152937. <https://doi.org/10.1016/j.prp.2020.152937> (2020).
64. Li, M. W. et al. Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B-cell lymphoma. *Cancer Med.* **12**, 3812–3829. <https://doi.org/10.1002/cam4.5115> (2023).
65. Ding, Y. et al. Downregulation of snoRNA SNORA52 and its clinical significance in hepatocellular carcinoma. *Biomed. Res. Int.* **2021**, 7020637. <https://doi.org/10.1155/2021/7020637> (2021).

66. Xie, Q. et al. Identification of key snoRNAs serves as biomarkers for hepatocellular carcinoma by bioinformatics methods. *Medicine (Baltimore)* <https://doi.org/10.1097/MD.00000000000030813> (2022).
67. Lopez-Corral, L. et al. Genomic analysis of high-risk smoldering multiple myeloma. *Haematologica* **97**, 1439–1443. <https://doi.org/10.3324/haematol.2011.060780> (2012).
68. Zhang, L., Xin, M. & Wang, P. Identification of a novel snoRNA expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on RNA sequencing dataset. *Math. Biosci. Eng.* **18**, 7837–7860. <https://doi.org/10.3934/mbe.2021389> (2021).
69. Gao, L. et al. Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing. *Int. J. Cancer* **136**, E623–629. <https://doi.org/10.1002/ijc.29169> (2015).
70. Liao, J. et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. *Mol. Cancer* **9**, 198. <https://doi.org/10.1186/1476-4598-9-198> (2010).
71. Dong, X. et al. Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer. *Thorac. Cancer* **12**, 659–666. <https://doi.org/10.1111/1759-7714.13823> (2021).
72. Zhou, H. et al. Identification of small nucleolar RNA SNORD60 as a potential biomarker and its clinical significance in lung adenocarcinoma. *Biomed. Res. Int.* **2022**, 5501171. <https://doi.org/10.1155/2022/5501171> (2022).
73. Wang, K. et al. Plasma SNORD83A as a potential biomarker for early diagnosis of non-small-cell lung cancer. *Future Oncol.* **18**, 821–832. <https://doi.org/10.2217/fo-2021-1278> (2022).
74. Zhu, W. et al. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway. *J. Transl. Med.* **17**, 259. <https://doi.org/10.1186/s12967-019-2005-1> (2019).
75. Kitagawa, T. et al. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer. *Mol. Oncol.* **13**, 212–227. <https://doi.org/10.1002/1878-0261.12398> (2019).
76. Nikas, J. B. & Nikas, E. G. Genome-wide DNA methylation model for the diagnosis of prostate cancer. *ACS Omega* **4**, 14895–14901. <https://doi.org/10.1021/acsomega.9b01613> (2019).
77. Zhang, Y. et al. A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma. *Cancer Cell Int.* **23**, 136. <https://doi.org/10.1186/s12935-023-02978-8> (2023).
78. Wang, L. Y. et al. Characterization the prognosis role and effects of snoRNAs in melanoma patients. *Exp. Dermatol.* **33**, e14944. <https://doi.org/10.1111/exd.14944> (2024).
79. Yi, Q. & Zou, W. J. A novel four-snoRNA signature for predicting the survival of patients with uveal melanoma. *Mol. Med. Rep.* **19**, 1294–1301. <https://doi.org/10.3892/mmr.2018.9766> (2019).
80. Gong, J. et al. A pan-cancer analysis of the expression and clinical relevance of small nucleolar RNAs in human cancer. *Cell Rep.* **21**, 1968–1981. <https://doi.org/10.1016/j.celrep.2017.10.070> (2017).
81. Cui, C. et al. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. *Oncogene* **40**, 909–921. <https://doi.org/10.1038/s41388-020-01570-y> (2021).
82. Faucher-Giguere, L. et al. High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival. *NAR Cancer* <https://doi.org/10.1093/narcan/zcab050> (2022).
83. Xu, A. et al. LncRNA H19 suppresses osteosarcomagenesis by regulating snoRNAs and DNA repair protein complexes. *Front. Genet.* **11**, 611823. <https://doi.org/10.3389/fgene.2020.611823> (2020).
84. Chen, F., Zheng, Y., Zhou, H. & Li, C. The regulatory role of SNORD35A in pancreatic cancer involves the HGF/C-met pathway. *Cancer Biother. Radiopharm* **39**, 211–222. <https://doi.org/10.1089/cbr.2022.0018> (2024).
85. Xu, B. et al. SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma. *Oncotarget* **8**, 43953–43966. <https://doi.org/10.18632/oncotarget.16693> (2017).
86. McMahon, M. et al. A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS. *Elife* <https://doi.org/10.7554/eLife.48847> (2019).
87. Che, Y. et al. KRAS regulation by small non-coding RNAs and SNARE proteins. *Nat. Commun.* **10**, 5118. <https://doi.org/10.1038/s41467-019-13106-4> (2019).
88. Patil, P. et al. scaRNAs regulate splicing and vertebrate heart development. *Biochim. Biophys. Acta* **1619–1629**, 2015. <https://doi.org/10.1016/j.bbadis.2015.04.016> (1852).
89. Falaleeva, M. et al. Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E1625–1634. <https://doi.org/10.1073/pnas.1519292113> (2016).
90. Huang, C. et al. A snoRNA modulates mRNA 3' end processing and regulates the expression of a subset of mRNAs. *Nucleic Acids Res.* **45**, 8647–8660. <https://doi.org/10.1093/nar/gkx651> (2017).
91. Sharma, E., Sterne-Weiler, T., O'Hanlon, D. & Blencowe, B. J. Global mapping of human RNA-RNA interactions. *Mol. Cell* **62**, 618–626. <https://doi.org/10.1016/j.molcel.2016.04.030> (2016).
92. Chabronova, A. et al. Depletion of SNORA33 abolishes psi of 28S-U4966 and affects the ribosome translational apparatus. *Int. J. Mol. Sci.* <https://doi.org/10.3390/ijms241612578> (2023).

Acknowledgements

The authors thank all patients for their participation in this study.

Author contributions

ANH performed data analysis, generated all article figures, and wrote the article. VDG and HJA conceived and designed the study; VDG supervised the research study; JP, LP, SM, OC, DOA, KR and RB supported the experimental work; SM supported the final review and editing; DB, MB, ND, DY, DD, and KB recruited participants, executed clinical protocols, and collected samples and clinical data. All co-authors critically reviewed the article.

Funding

Open access funding provided by the National Institutes of Health. This work was supported by funding provided by an NIAID-NCI research grant (Viral Hepatitis and Liver Cancer Research: U.S.-Mongolia Pilot Collaborative Award Program, 2016) and by the Intramural Research Program of the NIH Clinical Center (1ZIA-CL002121-11). The contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-026-35041-3>.

Correspondence and requests for materials should be addressed to A.N.H. or V.D.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2026